OZGENE PTY LTD

OZGENE PTY LTD specializes in advanced genetic engineering and preclinical model development for biomedical research, leveraging CRISPR, transgenic, and gene targeting technologies to create custom animal models for pharmaceutical and academic clients. The company’s core capabilities include precision genome editing, embryonic stem cell manipulation, and in vivo phenotyping workflows, with a focus on generating disease-relevant models for oncology, neurodegeneration, and immunology research. Their technical expertise centers on somatic cell nuclear transfer, conditional knockout systems, and transgene expression control, enabling highly reproducible, human-relevant preclinical platforms. OZGENE distinguishes itself through end-to-end model design, breeding colony management, and quality-controlled phenotypic characterization, ensuring compliance with international standards for laboratory animal welfare and genetic integrity. Award history is not available to determine specific agency engagements or contract patterns, so no definitive agency relationships can be identified. Similarly, without contract data, industry focus cannot be precisely mapped to NAICS categories or vertical markets, though the nature of their work suggests alignment with biomedical R&D and life sciences contract research. The company is structured as a proprietary entity based in Bentley, Australia, with no publicly disclosed government certifications. Its operations are centered on research and development services for global biopharmaceutical clients, positioning it within the international life sciences contract research market rather than the U.S. federal procurement ecosystem. Geographic presence is limited to its Australian facility, with no indication of U.S. federal market participation or certifications.